PT2988780T - Polipeptídeos f de pré-fusão do rsv solúveis estabilizados - Google Patents

Polipeptídeos f de pré-fusão do rsv solúveis estabilizados

Info

Publication number: PT2988780T
Authority: PT; Portugal
Prior art keywords: polypeptides; stabilized soluble; prefusion rsv; soluble prefusion; rsv
Prior art date: 2013-04-25

Application number

PT14719022T

Other languages

English (en)

Inventor

Petrus Maria Langedijk Johannes

Krarup Anders

Original Assignee

Janssen Vaccines & Prevention Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-25

Filing date

2014-04-24

Publication date

2019-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2988780(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-24 Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv

2019-03-25 Publication of PT2988780T publication Critical patent/PT2988780T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT14719022T 2013-04-25 2014-04-24 Polipeptídeos f de pré-fusão do rsv solúveis estabilizados PT2988780T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP13165402		2013-04-25

Publications (1)

Publication Number	Publication Date
PT2988780T true PT2988780T (pt)	2019-03-25

Family

ID=48326107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT14719022T PT2988780T (pt)	2013-04-25	2014-04-24	Polipeptídeos f de pré-fusão do rsv solúveis estabilizados

Country Status (33)

Country	Link
US (3)	US10899800B2 (pt)
EP (2)	EP3488864A1 (pt)
JP (1)	JP6469081B2 (pt)
KR (1)	KR102236497B1 (pt)
CN (2)	CN105188745B (pt)
AP (1)	AP2015008815A0 (pt)
AR (1)	AR096113A1 (pt)
AU (1)	AU2014259474B2 (pt)
CA (1)	CA2910067C (pt)
CL (1)	CL2015003124A1 (pt)
CY (1)	CY1121600T1 (pt)
DK (1)	DK2988780T3 (pt)
EA (2)	EA035522B1 (pt)
ES (1)	ES2715378T3 (pt)
HR (1)	HRP20190175T1 (pt)
HU (1)	HUE041659T2 (pt)
IL (1)	IL242186B (pt)
LT (1)	LT2988780T (pt)
ME (1)	ME03442B (pt)
MX (1)	MX361774B (pt)
MY (2)	MY181066A (pt)
PE (1)	PE20151867A1 (pt)
PH (1)	PH12015502377B1 (pt)
PL (1)	PL2988780T3 (pt)
PT (1)	PT2988780T (pt)
RS (1)	RS58436B1 (pt)
SG (1)	SG11201508567XA (pt)
SI (1)	SI2988780T1 (pt)
SM (1)	SMT201900138T1 (pt)
TR (1)	TR201902513T4 (pt)
TW (1)	TWI663175B (pt)
WO (1)	WO2014174018A1 (pt)
ZA (1)	ZA201507912B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11446374B2 (en)	2008-12-09	2022-09-20	Novavax, Inc.	Modified RSV F proteins and methods of their use
RU2531510C2 (ru)	2008-12-09	2014-10-20	Новавакс, Инк.	Модифицированные f протеины sv и способы их применения
US9738689B2 (en)	2013-03-13	2017-08-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Prefusion RSV F proteins and their use
WO2014160463A1 (en)	2013-03-13	2014-10-02	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prefusion rsv f proteins and their use
TR201902513T4 (tr)	2013-04-25	2019-03-21	Janssen Vaccines & Prevention Bv	Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es)	2013-06-17	2016-02-18	Crucell Holland Bv	Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
US10744193B2 (en)	2015-03-30	2020-08-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Immunogenic RSV polypeptides
AU2016289492B2 (en)	2015-07-07	2022-08-11	Janssen Vaccines & Prevention B.V.	Vaccine against RSV
BR112017028449A2 (pt) *	2015-07-07	2018-09-04	Janssen Vaccines & Prevention Bv	polipeptídeos rsv f pré-fusão solúveis estabilizados
EP4019044A3 (en)	2015-09-02	2022-08-24	Janssen Vaccines & Prevention B.V.	Stabilized viral class i fusion proteins
KR102667355B1 (ko)	2015-09-03	2024-05-20	노바백스, 인코포레이티드	개선된 안정성 및 면역원성을 갖는 백신 조성물
PT3393512T (pt)	2015-12-23	2026-01-16	Pfizer Inc	Mutantes de proteína f de rsv
EA037206B1 (ru)	2016-02-03	2021-02-19	Янссен Сайенсиз Айрлэнд Юси	Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе
CA3015570A1 (en)	2016-03-29	2017-10-05	Peter Kwong	Substitutions-modified prefusion rsv f proteins and their use
ES2858315T3 (es) *	2016-04-05	2021-09-30	Janssen Vaccines & Prevention Bv	Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru) *	2016-04-05	2019-03-29	Янссен Вэксинс Энд Превеншн Б.В.	Вакцина против rsv
WO2017207477A1 (en)	2016-05-30	2017-12-07	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
IL264119B2 (en) *	2016-05-30	2023-04-01	Janssen Vaccines Prevention B V	f proteins of rsv are stabilized before fusion
CN108265079A (zh) *	2017-01-02	2018-07-10	刘昕	一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
EP3595713A4 (en)	2017-03-15	2021-01-13	ModernaTX, Inc.	RESPIRATORY SYNCYTIAL VIRUS Vaccine
EP3595676A4 (en)	2017-03-17	2021-05-05	Modernatx, Inc.	RNA VACCINES AGAINST ZOONOSES
AU2018249533C1 (en)	2017-04-04	2023-10-12	Institute For Research In Biomedicine	Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP3624844A1 (en)	2017-05-17	2020-03-25	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
ES3028362T3 (en)	2017-07-24	2025-06-19	Novavax Inc	Methods and compositions for treating respiratory disease
US11229695B2 (en) *	2017-09-15	2022-01-25	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against RSV
KR102700187B1 (ko) *	2017-09-29	2024-08-28	에스케이바이오사이언스(주)	가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원
EP3746090A4 (en)	2018-01-29	2021-11-17	ModernaTX, Inc.	RSV RNA Vaccines
EP3768308A4 (en)	2018-03-19	2022-01-26	Novavax, Inc.	MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
US12370252B2 (en) *	2018-10-29	2025-07-29	Emory University	RSV virus-like particles and methods of use thereof
EP3880243A1 (en) *	2018-11-13	2021-09-22	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
CN109851678A (zh) *	2019-03-07	2019-06-07	苏州宇之波生物科技有限公司	一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
JP2022532742A (ja)	2019-05-15	2022-07-19	ヤンセンファッシンズアンドプリベンションベーフェー	アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
EP3969044A1 (en)	2019-05-15	2022-03-23	Janssen Vaccines & Prevention B.V.	Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
WO2021046207A1 (en)	2019-09-04	2021-03-11	University Of Washington	Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN111303245B (zh) *	2020-02-21	2023-06-27	成都奥达生物科技有限公司	一种抗合胞病毒膜融合抑制剂
CN115461076A (zh)	2020-04-02	2022-12-09	扬森疫苗与预防公司	稳定化的疫苗组合物
BR112022026408A2 (pt)	2020-06-29	2023-01-17	Janssen Vaccines & Prevention Bv	Combinação vacinal contra infecção pelo vírus sincicial respiratório
CN112220921B (zh)	2020-08-25	2022-08-16	北京交通大学	一种针对呼吸道合胞病毒感染的组合疫苗
JP2022060169A (ja)	2020-10-02	2022-04-14	ファイザー・インク	Ｒｓｖｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en)	2021-02-19	2022-08-25	Janssen Vaccines & Prevention B.V.	Vaccine combinations against respiratory syncytial virus strain a and b infections
CN114195867B (zh) *	2021-12-15	2024-05-03	北京交通大学	一种rsv融合前f蛋白、表达质粒、细胞株和rsv疫苗组合物
EP4448802A1 (en)	2021-12-16	2024-10-23	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion hmpv fusion proteins
EP4578870A1 (en) *	2022-09-29	2025-07-02	Beijing Benewill Technology Development Co., Ltd.	Respiratory syncytial virus recombinant fusion protein with prefusion conformation, and preparation method therefor and use thereof
IL319340A (en)	2022-09-29	2025-05-01	Pfizer	Immunogenic preparations containing RSV F protein truncation
CN116478296B (zh) *	2022-10-17	2024-02-23	厦门大学	截短的呼吸道合胞病毒f蛋白及其用途
WO2024089634A1 (en)	2022-10-27	2024-05-02	Pfizer Inc.	Immunogenic compositions against influenza and rsv
CN120153078A (zh)	2022-10-27	2025-06-13	辉瑞大药厂	编码rsv-f的rna分子及含所述rna分子的疫苗
CN116284266B (zh) *	2022-11-21	2024-01-19	怡道生物科技(苏州)有限公司	突变型呼吸道合胞病毒融合前f蛋白及其应用
JP2026500218A (ja)	2022-12-11	2026-01-06	ファイザー・インク	インフルエンザおよびｒｓｖに対する免疫原性組成物
JP2026503111A (ja) *	2023-01-17	2026-01-27	ザスクリプスリサーチインスティテュート	操作されたパラミクソウイルス可溶性融合（ｆ）タンパク質及び関連するワクチン
TW202436325A (zh)	2023-01-18	2024-09-16	美商輝瑞大藥廠	針對呼吸道疾病之疫苗
AU2024219190A1 (en) *	2023-02-06	2025-08-28	Cyanvac Llc	Modified piv5 vaccine vectors: methods of making and uses
CN118108812B (zh) *	2023-05-04	2025-04-15	国药中生生物技术研究院有限公司	Rsv f蛋白的突变体
CN117050149B (zh) *	2023-05-19	2025-12-12	珠海丽凡达生物技术有限公司	包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN121464149A (zh)	2023-06-07	2026-02-03	四川三叶草生物制药有限公司	Rsv疫苗组合物、方法及其用途
WO2025012756A1 (en)	2023-07-07	2025-01-16	Pfizer Inc.	Amphiphilic tlr7/8 adjuvants and uses thereof
CN119462859A (zh) *	2023-08-09	2025-02-18	深圳瑞吉生物科技有限公司	呼吸道合胞病毒抗原性多肽、疫苗及其应用
CN116785421B (zh) *	2023-08-21	2024-01-09	中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心）	一种牛呼吸道合胞体病毒的mRNA疫苗及其应用
CN119569835A (zh) *	2023-09-07	2025-03-07	北京科兴中维生物技术有限公司	呼吸道合胞病毒f蛋白及其应用
TW202515998A (zh) *	2023-09-15	2025-04-16	美商伊科薩瓦克斯有限公司	病毒蛋白質及奈米結構及其用途
WO2025126071A1 (en)	2023-12-14	2025-06-19	Pfizer Inc.	Rna molecules
CN117736278B (zh) *	2023-12-25	2025-02-07	英诺特（唐山）生物技术有限公司	一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
TW202536184A (zh) *	2024-01-11	2025-09-16	大陸商嘉晨西海（杭州）生物技術有限公司	呼吸道融合病毒疫苗組合物及其用途
CN117586357B (zh) *	2024-01-19	2024-07-09	北京安百胜生物科技有限公司	一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2025163460A2 (en)	2024-01-30	2025-08-07	Pfizer Inc.	Vaccines against respiratory diseases
WO2025186719A1 (en)	2024-03-06	2025-09-12	Pfizer Inc.	Immunogenic compositions and uses thereof
CN121022942A (zh) *	2024-05-27	2025-11-28	广州国家实验室	腺相关病毒载体在制备防治rsv感染和/或rsv引起的疾病的药物中的应用
US20260021175A1 (en)	2024-07-17	2026-01-22	Pfizer Inc.	Immunogenic compositions and uses thereof
CN120192386A (zh) *	2025-02-07	2025-06-24	复星安特金(成都)生物制药有限公司	Rsv f蛋白突变体及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en)	1984-08-24	1991-10-09	The Upjohn Company	Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
NZ230747A (en)	1988-09-30	1992-05-26	Bror Morein	Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr)	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en)	1994-06-10	1998-12-22	Genvec, Inc.	Complementary adenoviral systems and cell lines
EP1548118A2 (en)	1994-06-10	2005-06-29	Genvec, Inc.	Complementary adenoviral vector systems and cell lines
US5846782A (en)	1995-11-28	1998-12-08	Genvec, Inc.	Targeting adenovirus with use of constrained peptide motifs
US5965541A (en)	1995-11-28	1999-10-12	Genvec, Inc.	Vectors and methods for gene transfer to cells
US5559099A (en)	1994-09-08	1996-09-24	Genvec, Inc.	Penton base protein and methods of using same
US5786464C1 (en)	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
US5837520A (en)	1995-03-07	1998-11-17	Canji, Inc.	Method of purification of viral vectors
IL122614A0 (en)	1995-06-15	1998-08-16	Introgene Bv	Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en)	1995-10-02	1998-11-17	Cornell Research Foundation, Inc.	Non-group C adenoviral vectors
CA2177085C (en)	1996-04-26	2007-08-14	National Research Council Of Canada	Adenovirus e1-complementing cell lines
IL127692A0 (en)	1996-07-01	1999-10-28	Rhone Poulenc Rorer Sa	Method for producing recombinant adenovirus
FR2751343B1 (fr)	1996-07-16	1998-12-18	Transgene Sa	Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998010087A1 (en)	1996-09-06	1998-03-12	Trustees Of The University Of Pennsylvania	Chimpanzee adenovirus vectors
WO1998022588A2 (en)	1996-11-20	1998-05-28	Introgen Therapeutics, Inc.	An improved method for the production and purification of adenoviral vectors
US7732129B1 (en)	1998-12-01	2010-06-08	Crucell Holland B.V.	Method for the production and purification of adenoviral vectors
US6261823B1 (en)	1996-12-13	2001-07-17	Schering Corporation	Methods for purifying viruses
JP2000509614A (ja)	1997-03-04	2000-08-02	バクスターインターナショナルインコーポレイテッド	アデノウイルスｅ１−相補性細胞系
US6020191A (en)	1997-04-14	2000-02-01	Genzyme Corporation	Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en)	1997-09-05	2001-04-03	Merck & Co., Inc.	Stabilizers containing recombinant human serum albumin for live virus vaccines
IL137510A0 (en)	1998-02-17	2001-07-24	Schering Corp	Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en)	1998-04-16	1999-11-09	Baylor College Of Medicine	Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en)	1998-06-26	2000-09-05	Genvec, Inc.	Recombinant adenovirus
ATE421337T1 (de)	1998-11-16	2009-02-15	Introgen Therapeutics Inc	Adenovirus-formulierungen zur gentherapie
US6225289B1 (en)	1998-12-10	2001-05-01	Genvec, Inc.	Methods and compositions for preserving adenoviral vectors
PT1818408E (pt)	1999-05-17	2011-11-15	Crucell Holland Bv	Adenovírus recombinante do serótipo ad11
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
DE19955558C2 (de)	1999-11-18	2003-03-20	Stefan Kochanek	Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP2420247A1 (en)	2000-03-07	2012-02-22	Merck Sharp & Dohme Corp.	Adenovirus formulations
EP1287159A4 (en)	2000-05-08	2005-02-09	Davisco Foods Int Inc	Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en)	2001-11-09	2001-12-06	Biota Holdings Ltd	Methods for identifying or screening anti-viral agents
CA2469623C (en)	2001-12-12	2012-05-29	F H Faulding & Co Limited	Composition for the preservation of viruses
BR0306925A (pt)	2002-01-18	2004-11-09	Schering Ag	Formulações estabilizadas de adenovìrus
US20030180936A1 (en)	2002-03-15	2003-09-25	Memarzadeh Bahram Eric	Method for the purification, production and formulation of oncolytic adenoviruses
KR101006594B1 (ko)	2002-04-25	2011-01-07	크루셀 홀란드 비.브이.	안정한 아데노바이러스 벡터 및 그 증식 방법
MXPA04008891A (es)	2002-04-25	2004-11-26	Crucell Holland Bv	Medios y metodos para la produccion de vectores de adenovirus.
PT1506287E (pt)	2002-05-14	2007-07-17	Merck & Co Inc	Métodos de purificação de adenovírus
SE0202110D0 (sv)	2002-07-05	2002-07-05	Isconova Ab	Iscom preparation and use thereof
US20040106184A1 (en)	2002-08-28	2004-06-03	Introgen Therapeutics Inc.	Chromatographic methods for adenovirus purification
SE0301998D0 (sv)	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof
CA2880060C (en)	2004-01-23	2018-03-13	Agostino Cirillo	Chimpanzee adenovirus vaccine carriers
US20070207461A1 (en)	2004-02-23	2007-09-06	Crucell Holland B.V.	Virus Purification Methods
CA2602944C (en)	2005-04-11	2015-08-11	Crucell Holland B.V.	Virus purification using ultrafiltration
WO2007104792A2 (en)	2006-03-16	2007-09-20	Crucell Holland B.V.	Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en)	2006-03-27	2007-10-04	Crucell Holland B.V.	Compositions comprising a recombinant adenovirus and an adjuvant
US8772256B2 (en)	2006-11-30	2014-07-08	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Codon modified immunogenic compositions and methods of use
US7901388B2 (en)	2007-07-13	2011-03-08	Bacoustics, Llc	Method of treating wounds by creating a therapeutic solution with ultrasonic waves
CN101952321B (zh) *	2007-12-24	2016-05-11	葛兰素史密斯克莱生物公司	重组rsv抗原
WO2010014975A2 (en)	2008-08-01	2010-02-04	Academia Sinica	Use of microrna signatures for assessing risk levels of neuroblastoma patients
WO2010060719A1 (en)	2008-11-03	2010-06-03	Crucell Holland B.V.	Method for the production of adenoviral vectors
MX2011007980A (es)	2009-02-02	2011-08-17	Okairos Ag	Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
UA111141C2 (uk)	2009-06-24	2016-04-11	Глаксосмітклайн Байолоджікалз С.А.	Рекомбінантні антигени рсв
AU2010264686A1 (en)	2009-06-24	2012-01-19	Glaxosmithkline Biologicals S.A.	Vaccine
ES2918381T3 (es) *	2009-07-15	2022-07-15	Glaxosmithkline Biologicals Sa	Composiciones de proteína F de VRS y métodos para producir las mismas
BR112012003064B8 (pt)	2009-08-13	2021-05-25	Crucell Holland Bv	anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
PL2488635T3 (pl)	2009-10-15	2014-04-30	Crucell Holland Bv	Proces do oczyszczania adenowirusa z hodowli o dużej gęstości komórek
AU2010305765B2 (en)	2009-10-15	2015-07-02	Crucell Holland B.V.	Method for the purification of adenovirus particles
WO2011050168A2 (en) *	2009-10-21	2011-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Rsv immunogens, antibodies and compositions thereof
PL2536829T3 (pl)	2010-02-15	2016-09-30		Sposób wytwarzania wektorów adenowirusowych Ad26
US9139642B2 (en) *	2010-07-09	2015-09-22	Crucell Holland B.V.	Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
AU2012255971A1 (en)	2011-05-13	2013-05-02	Novartis Ag	Pre-fusion RSV F antigens
PL2825640T3 (pl)	2012-03-12	2016-10-31		Partie rekombinowanych adenowirusów o zmienionych końcach
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
SG11201405804YA (en)	2012-03-22	2014-10-30	Crucell Holland Bv	Vaccine against rsv
JP2013247240A (ja)	2012-05-25	2013-12-09	Gigaphoton Inc	レーザ装置
WO2014005643A1 (en)	2012-07-05	2014-01-09	Okairos Ag	Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
WO2014160463A1 (en)	2013-03-13	2014-10-02	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prefusion rsv f proteins and their use
US9738689B2 (en) *	2013-03-13	2017-08-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Prefusion RSV F proteins and their use
US10035842B2 (en)	2013-04-15	2018-07-31	Janssen Vaccines & Prevention B.V.	Human antibodies binding to RSV G proteins
CN105189547B (zh)	2013-04-15	2020-01-17	扬森疫苗与预防公司	结合到rsv g蛋白的人类抗体
TR201902513T4 (tr)	2013-04-25	2019-03-21	Janssen Vaccines & Prevention Bv	Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es)	2013-06-17	2016-02-18	Crucell Holland Bv	Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2015013551A1 (en)	2013-07-25	2015-01-29	Marshall Christopher Patrick	Conformationally stabilized rsv pre-fusion f proteins
PL3046536T3 (pl)	2013-09-19	2019-06-28	Janssen Vaccines & Prevention B.V.	Ulepszone formulacje adenowirusów
ES2858315T3 (es) *	2016-04-05	2021-09-30	Janssen Vaccines & Prevention Bv	Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru)	2016-04-05	2019-03-29	Янссен Вэксинс Энд Превеншн Б.В.	Вакцина против rsv

2014
- 2014-04-24 TR TR2019/02513T patent/TR201902513T4/tr unknown
- 2014-04-24 EA EA201592048A patent/EA035522B1/ru unknown
- 2014-04-24 WO PCT/EP2014/058353 patent/WO2014174018A1/en not_active Ceased
- 2014-04-24 CA CA2910067A patent/CA2910067C/en active Active
- 2014-04-24 EP EP18205858.6A patent/EP3488864A1/en active Pending
- 2014-04-24 LT LTEP14719022.7T patent/LT2988780T/lt unknown
- 2014-04-24 MY MYPI2015703748A patent/MY181066A/en unknown
- 2014-04-24 HR HRP20190175TT patent/HRP20190175T1/hr unknown
- 2014-04-24 EA EA202090675A patent/EA039803B1/ru unknown
- 2014-04-24 SI SI201431056T patent/SI2988780T1/sl unknown
- 2014-04-24 PL PL14719022T patent/PL2988780T3/pl unknown
- 2014-04-24 MX MX2015014890A patent/MX361774B/es active IP Right Grant
- 2014-04-24 HU HUE14719022A patent/HUE041659T2/hu unknown
- 2014-04-24 ES ES14719022T patent/ES2715378T3/es active Active
- 2014-04-24 PT PT14719022T patent/PT2988780T/pt unknown
- 2014-04-24 DK DK14719022.7T patent/DK2988780T3/en active
- 2014-04-24 AU AU2014259474A patent/AU2014259474B2/en not_active Ceased
- 2014-04-24 PE PE2015002278A patent/PE20151867A1/es unknown
- 2014-04-24 ME MEP-2019-73A patent/ME03442B/me unknown
- 2014-04-24 JP JP2016509467A patent/JP6469081B2/ja not_active Expired - Fee Related
- 2014-04-24 RS RS20190170A patent/RS58436B1/sr unknown
- 2014-04-24 KR KR1020157032796A patent/KR102236497B1/ko not_active Expired - Fee Related
- 2014-04-24 SG SG11201508567XA patent/SG11201508567XA/en unknown
- 2014-04-24 AP AP2015008815A patent/AP2015008815A0/xx unknown
- 2014-04-24 CN CN201480023229.5A patent/CN105188745B/zh active Active
- 2014-04-24 EP EP14719022.7A patent/EP2988780B1/en active Active
- 2014-04-24 SM SM20190138T patent/SMT201900138T1/it unknown
- 2014-04-24 CN CN201910911639.8A patent/CN110590916A/zh active Pending
- 2014-04-24 US US14/786,955 patent/US10899800B2/en active Active
- 2014-04-25 AR ARP140101738A patent/AR096113A1/es not_active Application Discontinuation
- 2014-04-25 TW TW103115087A patent/TWI663175B/zh active
2015
- 2015-10-13 PH PH12015502377A patent/PH12015502377B1/en unknown
- 2015-10-20 IL IL242186A patent/IL242186B/en active IP Right Grant
- 2015-10-22 CL CL2015003124A patent/CL2015003124A1/es unknown
- 2015-10-23 ZA ZA2015/07912A patent/ZA201507912B/en unknown
2018
- 2018-11-29 MY MYPI2018002243A patent/MY201791A/en unknown
2019
- 2019-03-13 CY CY20191100303T patent/CY1121600T1/el unknown
2020
- 2020-12-18 US US17/126,128 patent/US20210101940A1/en not_active Abandoned
2022
- 2022-08-23 US US17/821,694 patent/US20230265127A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA202090675A3 (ru)	2020-08-31
MX361774B (es)	2018-12-17
EP3488864A1 (en)	2019-05-29
HK1220124A1 (en)	2017-04-28
PL2988780T3 (pl)	2019-06-28
US20230265127A1 (en)	2023-08-24
CL2015003124A1 (es)	2016-05-13
PH12015502377A1 (en)	2016-02-22
CA2910067C (en)	2023-10-17
IL242186B (en)	2020-07-30
ZA201507912B (en)	2022-03-30
KR20160002938A (ko)	2016-01-08
PE20151867A1 (es)	2016-01-07
US20210101940A1 (en)	2021-04-08
ME03442B (me)	2020-01-20
MX2015014890A (es)	2016-03-09
RS58436B1 (sr)	2019-04-30
JP2016520039A (ja)	2016-07-11
WO2014174018A1 (en)	2014-10-30
TR201902513T4 (tr)	2019-03-21
MY181066A (en)	2020-12-17
HRP20190175T1 (hr)	2019-03-22
US10899800B2 (en)	2021-01-26
EP2988780B1 (en)	2018-12-26
CY1121600T1 (el)	2020-05-29
SMT201900138T1 (it)	2019-05-10
LT2988780T (lt)	2019-03-12
CN110590916A (zh)	2019-12-20
SG11201508567XA (en)	2015-11-27
SI2988780T1 (sl)	2019-05-31
NZ713371A (en)	2021-02-26
EA039803B1 (ru)	2022-03-15
EA035522B1 (ru)	2020-06-29
MY201791A (en)	2024-03-18
ES2715378T3 (es)	2019-06-04
KR102236497B1 (ko)	2021-04-06
AU2014259474A1 (en)	2015-11-05
DK2988780T3 (en)	2019-04-08
CA2910067A1 (en)	2014-10-30
HUE041659T2 (hu)	2019-05-28
TW201520221A (zh)	2015-06-01
CN105188745A (zh)	2015-12-23
CN105188745B (zh)	2019-10-18
TWI663175B (zh)	2019-06-21
EA201592048A1 (ru)	2016-04-29
AR096113A1 (es)	2015-12-09
EP2988780A1 (en)	2016-03-02
JP6469081B2 (ja)	2019-02-13
AP2015008815A0 (en)	2015-10-31
US20160102123A1 (en)	2016-04-14
PH12015502377B1 (en)	2021-09-08
AU2014259474B2 (en)	2018-09-13
EA202090675A2 (ru)	2020-06-30

Publication	Publication Date	Title
ZA201507912B (en)	2022-03-30	Stabilized soluble prefusion rsv f polypeptides
ZA201509140B (en)	2022-03-30	Stabilized soluble pre-fusion rsv f polypeptides
IL244943A0 (en)	2016-05-31	New amino pyrimidine histories
GB201401167D0 (en)	2014-03-12	Position sensor
EP2895819A4 (en)	2016-08-31	SENSOR FUSION
GB201311475D0 (en)	2013-08-14	Polypeptides
PL3024827T3 (pl)	2020-10-19	Podstawione pochodne chinazolin-4-onu
GB201321429D0 (en)	2014-01-15	Sensor
GB201322491D0 (en)	2014-02-05	Sensor
GB201306097D0 (en)	2013-05-22	Sensor
GB201301543D0 (en)	2013-03-13	Sensor
AP2015008892A0 (en)	2015-12-31	Stabilized soluble pre-fusion rsv f polypeptides
PL3014234T3 (pl)	2021-12-13	Czujnik
GB201309421D0 (en)	2013-07-10	Polypeptides
PL3080276T3 (pl)	2018-08-31	Polipeptydy toksyczne dla owadów
GB201305210D0 (en)	2013-05-01	Component sensor
GB201314490D0 (en)	2013-09-25	Position Sensor
GB201311400D0 (en)	2013-08-14	Position Sensor
GB201323061D0 (en)	2014-02-12	Sensor
GB201321388D0 (en)	2014-01-15	Sensor
GB201313025D0 (en)	2013-09-04	Sensor
GB201308817D0 (en)	2013-07-03	Sensor element